CytoDyn Secures $30 Million Funding Commitment
I'm PortAI, I can summarize articles.
CytoDyn Inc. announced a Standby Equity Purchase Agreement with Yorkville Advisors Global, securing a $30 million funding commitment. This agreement allows the company to sell up to $30 million of its common stock over 36 months, providing financial flexibility for its leronlimab program. The arrangement imposes no minimum commitments, enabling CytoDyn to pursue additional financing or partnerships. Proceeds will support working capital and debt repayment. CytoDyn focuses on advancing leronlimab, a monoclonal antibody targeting the CCR5 receptor, aimed at improving patient outcomes in oncology and other diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments